Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.
This bill adds Medicare coverage for defined multi-cancer early detection (MCED) screening tests beginning January 1, 2028, if the Secretary of HHS determines them reasonable and necessary using the national coverage determination process. It defines eligible tests (FDA-cleared/approved and typically genomic blood tests analyzing cell-free nucleic acids or comparable samples) and sets payment rules tied initially to the payment amount for multi-target stool DNA tests through 2030, with a new pricing rule thereafter.
Liberals emphasize population health and access; conservatives stress cost and evidence.
Relative to its intended legislative type, this bill is a well-specified substantive coverage amendment: it adds a defined category of Medicare-covered tests, prescribes payment formulas and limits, uses established coverage processes (NCD, USPSTF), and includes conforming statutory changes.
This bill adds Medicare coverage for defined multi-cancer early detection (MCED) screening tests beginning January 1, 2028, if the Secretary of HHS determines them reasonable and necessary using the national coverage determination process.
It defines eligible tests (FDA-cleared/approved and typically genomic blood tests analyzing cell-free nucleic acids or comparable samples) and sets payment rules tied initially to the payment amount for multi-target stool DNA tests through 2030, with a new pricing rule thereafter.
The bill bars payment if an individual has attained a specified age (68 in 2028, increasing by one year annually) or received the test within the prior 11 months, and states that USPSTF A/B recommendations will supersede certain payment/limits.
Narrow, technical Medicare expansion with administrative safeguards boosts viability, but fiscal impact and clinical controversy moderate prospects.
Relative to its intended legislative type, this bill is a well-specified substantive coverage amendment: it adds a defined category of Medicare-covered tests, prescribes payment formulas and limits, uses established coverage processes (NCD, USPSTF), and includes conforming statutory changes. It delegates appropriate determinations to the Secretary but leaves operational, fiscal, and monitoring details to existing processes or future rulemaking.
Liberals emphasize population health and access; conservatives stress cost and evidence.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize population health and access; conservatives stress cost and evidence.
Generally supportive of expanding preventive cancer detection through Medicare, particularly genomic-based early detection.
Concerned about the bill's age‑based payment exclusion and access equity, and wary of any provisions that could delay coverage through bureaucratic processes.
Sees potential public-health benefits but wants stronger protections to ensure broad, equitable access.
Cautiously favorable toward covering validated MCED tests with evidence-based safeguards.
Values the NCD process and USPSTF linkage for rigorous review, but raises questions about the unusual age cutoff and the interim payment mechanism.
Wants clarity on costs, clinical effectiveness, and implementation timelines before full endorsement.
Skeptical of expanding Medicare coverage for new screening technologies without strong, long-term evidence and cost controls.
Concerned about increased Medicare spending, potential overdiagnosis, and setting payment precedents.
Prefers strict NCD application and tighter limits on reimbursement unless proven cost-effective.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, technical Medicare expansion with administrative safeguards boosts viability, but fiscal impact and clinical controversy moderate prospects.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize population health and access; conservatives stress cost and evidence.
Narrow, technical Medicare expansion with administrative safeguards boosts viability, but fiscal impact and clinical controversy moderate p…
Relative to its intended legislative type, this bill is a well-specified substantive coverage amendment: it adds a defined category of Medicare-covered tests, prescribes payment formulas and limits, uses established cov…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.